2186 — Luye Pharma Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapTurnaround

Annual cashflow statement for Luye Pharma, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	942	-74.6	670	700	839
Depreciation
Amortisation
Non-Cash Items	371	661	455	399	429
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-791	-986	-142	-206	-1,891
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	1,033	182	1,654	1,595	168
Capital Expenditures	-1,520	-1,542	-1,164	-1,165	-1,708
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	1,658	-1,894	-495	-253	237
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	138	-3,436	-1,658	-1,418	-1,471
Financing Cash Flow Items	-933	1,241	720	397	871
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	254	1,879	54.1	842	2,956
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	1,538	-1,427	-115	915	1,698